$MGTX

MeiraGTx Holdings plc (MGTX): Submission of Matters to a Vote of Security Holders

MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. MeiraGTx Holdings plc_June 11, 2026 0001735438 false 0001735438 2026-06-11 2026-06-11 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of

Original reporting
Published Jun 15, 2026, 8:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$MGTX
Neutral
high confidence
Mentioned
$MGTX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MGTXNeutralLow
01

Why it matters

This is a governance disclosure (director elections and independent auditor ratification) without accompanying financial guidance, clinical updates, or corporate actions.

02

Market read

Traders may treat this as low-signal housekeeping; any price effect would be sentiment-driven rather than catalyst-driven.

03

What to watch

The vote tallies alone don’t indicate whether any governance proposals were contentious; traders would need the underlying proxy statement for context on any high-stakes items.

Relevance 6/10Novelty 2/10Timing: Filed June 15, 2026 for the June 11, 2026 Annual Meeting vote results.

Background

The company submitted SEC Form 8-K under Item 5.07 summarizing results from its June 11, 2026 annual general meeting.

Company-level read

Ticker impact

$MGTXNeutralHigh confidence
Context

MeiraGTx filed an 8-K reporting Annual Meeting voting results, including election of three Class II directors and ratification of Ernst & Young for 2026.

Expected impact

Limited near-term impact; any reaction likely confined to governance/overhang sentiment rather than fundamentals.

Evidence & confidence

The filing only provides vote tallies for director elections and auditor ratification, with no new strategy, financial results, or regulatory/clinical catalysts.

Market effects

Minimal; auditor ratification and director elections are standard across biotech and do not signal sector-wide change.

Minimal; no cross-border transaction or regulatory action described.

Minimal; no global partnership, trial, or financing terms disclosed.

Counterpoint

If investors were concerned about board composition or auditor continuity, the confirmed outcomes could reduce uncertainty, but the filing provides no evidence of a contested or material dispute.

Key entities

  • MeiraGTx Holdings plc

    Nasdaq-listed company filing the 8-K with Annual Meeting voting results.

  • Ernst & Young LLP

    Ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

Related articles

$MGTXMed

MeiraGTx Holdings plc (MGTX): Results of Operations and Financial Condition

MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MeiraGTx Reports Second Quarter 2026 Financial and Operational Results - Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe

$MGTXMedAI 8/10

MeiraGTx secures $400m from Oberland Capital

MeiraGTx said it will receive up to $375m in non-dilutive capital from Oberland Capital via capped royalties, plus up to $25m in equity. An initial $135m was funded, including $125m in low single-digit royalties and a $10m equity stake. Additional payments total $150m tied to Phase II completion and regulatory approvals for AAV2-hAQP1 and bota-vec.

$MGTXMedAI 8/10

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MeiraGTx Holdings (Nasdaq: MGTX) said it agreed with Oberland Capital for up to $400m to fund development/commercialization of AAV2-hAQP1 (RIX), bota-vec (XLRP) and AAV-AIPL1. Oberland will provide up to $375m in non-dilutive capped royalty funding and up to $25m equity, with additional tranches tied to 2027–2028 data/approvals.

$OTEXHighAI 8/10

OPEN TEXT CORP (OTEX): Other Events

OPEN TEXT CORP (OTEX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 OpenText Announces Senior Secured Notes Offering to Redeem its Outstanding 2027 Notes and Fund Tender Offer for a Portion of its Outstanding 2028 Notes Waterloo, ON, September 23, 2026 – Open Text Corporation (the “Company” or “OpenText”) (NASDAQ: OTEX), (TSX: OTEX)

$BCDAMed

BioCardia, Inc. (BCDA): Other Events

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission SUNNYVALE, Calif. – September 23, 2026 – BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of ca

$CLow

Citigroup Announces €1.5 Billion Redemption of 0.500% Fixed Rate / Floating Rate Notes Due 2027

Citigroup Inc. announced the redemption of €1.5 billion of its 0.500% Fixed Rate/Floating Rate Notes due 2027. The redemption date is October 8, 2026, with the cash redemption price equal to par plus accrued interest. This move aligns with Citigroup's liability management strategy to optimize funding and capital structure. Citibank, N.A. serves as the paying agent for the notes.